PHOSPHOLIPASES AND ENDOTHELIAL CELL ACTIVATION

Information

  • Research Project
  • 3340061
  • ApplicationId
    3340061
  • Core Project Number
    R01HL028778
  • Full Project Number
    2R01HL028778-09A2
  • Serial Number
    28778
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/1/1987 - 37 years ago
  • Project End Date
    5/31/1997 - 27 years ago
  • Program Officer Name
  • Budget Start Date
    6/1/1993 - 31 years ago
  • Budget End Date
    5/31/1994 - 30 years ago
  • Fiscal Year
    1993
  • Support Year
    9
  • Suffix
    A2
  • Award Notice Date
    5/31/1993 - 31 years ago

PHOSPHOLIPASES AND ENDOTHELIAL CELL ACTIVATION

The broad long-term goal of the applicants is to increase knowledge of the role of phospholipases in signal transduction in endothelial cells. The importance of this information is greatly enhanced by the accumulating evidence implicating endothelial cells in the processes of coagulation, inflammation, thrombosis and atherosclerosis. The pro- and anti-thrombotic properties of endothelial cells can be altered by vasoactive and inflammatory mediators. Tumor angiogenesis and endothelial proliferation are regulated by growth factors. A very early event initiated by these mediators is activation of phospholipase C (PLC) which generates inositol 1,4,5-triphosphate and 1,2-diacylglycerol, two second messengers in signal transduction of ligand-receptor interactions. To better understand how endothelial cell and growth factor participate in normal and pathological angiogenic processes will require detailed knowledge of the intracellular signaling pathways. The studies proposed in this application shall provide information to three important aspects that have not yet been investigated. These are the mechanism of PLC- gamma activation, PLC activation in human endothelial cells and in association with vascular endothelial growth factor (VEGF). A better understanding of how endothelial cell activation in modulated may aid the development of better strategies for the prevention and treatment of cardiovascular and metastatic diseases. In this proposal, more specifically we propose the following lines of inquiry: 1. Investigate the role of PLC-gamma2 in signal transduction of epidermal growth factor (EGF) in human endothelial cells. We will determine if EGF activates PLC-gamma2, and if so, evaluate the activation mechanism of PLC-gamma2 by examining the effect of PLC-gamma2 phosphorylation on its catalytic activity and on the interaction with membrane. 2. Study the activation of PLC isozymes induced by VEGF in human endothelial cells. 3. Evaluate the modulation of the expression of PLC isozymes in in vitro endothelial cell culture. 4. Determine by in situ hybridization and immunohistochemistry the tissue specificity of PLC isozyme expression in the endothelium of normal tissues and inflammatory lesions. 5. Characterize a potentially unique gene induced by interleukin-1 in human endothelial cells.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R01
  • Administering IC
    HL
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    HEM
  • Study Section Name
    Hematology Subcommittee 2
  • Organization Name
    NEW ENGLAND DEACONESS HOSPITAL
  • Organization Department
  • Organization DUNS
  • Organization City
    BOSTON
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02215
  • Organization District
    UNITED STATES